TL;DR: A 2026 study in Signal Transduction and Targeted Therapy engineered a modified inhibitory DREADD receptor called GRANPA so the over-the-counter antihistamine diphenhydramine could switch off targeted brain circuits and reduce seizure activity in mouse models. Key Findings Two added receptor mutations: The lead GRANPA receptor combined hM4Di with S85V and Y416F mutations to improve …
TL;DR: A 2026 narrative review in Clinical Drug Investigation argued that desvenlafaxine, a serotonin-noradrenaline reuptake inhibitor (SNRI), may be a first-line major depressive disorder option for selected patients, especially when fatigue, cognitive complaints, polypharmacy, or tolerability concerns shape the treatment choice. Key Findings Review plus consensus: The source combined a PubMed-based narrative review with a …
TL;DR: A 2026 review in International Journal of Molecular Medicine mapped how exercise and fluoxetine overlap in Alzheimer’s disease mechanisms such as mitochondrial quality control, oxidative stress, inflammation, and neuroplasticity, but clinical combination benefits remain unproven. Key Findings Review article, not trial: Wu and Li synthesized mechanistic evidence on exercise and fluoxetine in Alzheimer’s disease …
TL;DR: A 2026 systematic review and meta-analysis in Bipolar Disorders found that poor medication adherence in bipolar disorder was linked to substance use, psychotic features, lower insight, poorer functioning, and several markers of more severe illness, but most evidence was graded low or very low quality. Key Findings 19 studies included: Researchers pooled observational studies …
TL;DR: A 2026 systematic review and meta-analysis in Brain, Behavior, & Immunity – Health found that adding celecoxib to antidepressants was linked to lower depressive symptom scores in 7 small trials, but the efficacy evidence was rated very low certainty. Key Findings 7 randomized trials: The meta-analysis included 365 adults with major depressive disorder, with …
TL;DR: A 2026 secondary analysis in Addiction found that adults switched to very-low-nicotine cigarettes often used alternative nicotine products and maintained much higher nicotine intake than cigarette-only users. Key Findings 438 smokers: The parent randomized clinical trial enrolled adults who smoked 5 to 40 cigarettes per day. 0.4 mg/g cigarettes: The very-low-nicotine-content group received Spectrum …
TL;DR: A 2026 systematic review in Future Science OA found early medication evidence for online behavioral addictions, but the 20 included studies were mostly small, male-heavy, and short-term. Key Findings Medication evidence stayed early: The review found small, mixed pharmacotherapy signals across 20 online behavioral addiction studies. Clinical groups stayed small: The 1,016 total participants …
TL;DR: A 2026 real-world study in Journal of Clinical Sleep Medicine found that glucagon-like peptide-1 receptor agonist use was associated with lower 3-year cardiovascular-event risk in adults with obesity and obstructive sleep apnea. Key Findings 18,523 matched pairs: Propensity matching compared GLP-1 receptor agonist users with similar non-users who had obesity and obstructive sleep apnea. …
TL;DR: A 2026 review in International Journal of Nanomedicine argued that depression nanomedicine should move beyond blood-brain-barrier delivery alone and be judged by target engagement, neuroimmune-barrier-plasticity effects, safety, manufacturability, and patient stratification. Key Findings Mechanism-centered review: The paper organized depression nanomedicine around neuroinflammation, blood-brain-barrier dysfunction, oxidative stress, and impaired neuroplasticity. 3 strategy groups: The review …
TL;DR: A 2026 study in European Archives of Psychiatry and Clinical Neuroscience linked sustained quetiapine treatment with better high-working-memory cognitive performance in schizophrenia spectrum disorder, but the genetic tests did not support the proposed remyelination-moderation mechanism. Key Findings 166 matched pairs: The extended PsyCourse analysis included 166 quetiapine-treated schizophrenia-spectrum patients and 166 age- and sex-matched …
